Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP) P. Petitpretz, C. Chidiac, F. Soriano, J. Garau, K. Stevenson, E. Rouffiac (Le Chesnay, Versailles, Lyon, Nanterre, France; Madrid, Barcelona, Spain; Harlow, United Kingdom)
Source: Annual Congress 2001 - Treatment of LRTI
Session: Treatment of LRTI Session type: Thematic Poster Session Number: 920
Disease area: Respiratory infectionsRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Petitpretz, C. Chidiac, F. Soriano, J. Garau, K. Stevenson, E. Rouffiac (Le Chesnay, Versailles, Lyon, Nanterre, France; Madrid, Barcelona, Spain; Harlow, United Kingdom). Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP). Eur Respir J 2001; 16: Suppl. 31, 920
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Comparison of the adherence of the oral pharmacokinetically enhanced formulation of amoxicillin/clavulanic acid 2,000/125 mg twice daily with that of the standard formulation of amoxicillin/clavulanic acid 500/125 mg thrice daily Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Pharmacokinetics of consecutive oral moxifloxacin 400 mg/day in patients with respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Comparative trial of cefuroxime 250 mg with probenecid 250 mg with cefuroxime 500 mg in lower respiratory tract infection Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 143s Year: 2003
The effect of esomeprazole 40mg once or twice daily on asthma outcome Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Clinical efficacy of bolus versus continuous-infusion of piperacillin-tazobactam in VAP treatment Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019
Efficacy of sequential intravenous (i.v. ) to oral (p.o. ) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp. Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006